Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Non-cash Items (2018 - 2022)

Kiora Pharmaceuticals (KPRX) has disclosed Non-cash Items for 5 consecutive years, with $429000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Non-cash Items rose 113.97% year-over-year to $429000.0, compared with a TTM value of $429000.0 through Sep 2022, up 113.97%, and an annual FY2021 reading of $201653.0, up 41.95% over the prior year.
  • Non-cash Items was $429000.0 for Q3 2022 at Kiora Pharmaceuticals, down from $473000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $1.4 million in Q2 2018 and bottomed at $96863.0 in Q3 2018.
  • Average Non-cash Items over 5 years is $285847.4, with a median of $142061.0 recorded in 2020.
  • The sharpest move saw Non-cash Items tumbled 92.3% in 2019, then soared 267.5% in 2022.
  • Year by year, Non-cash Items stood at $96863.0 in 2018, then grew by 21.34% to $117534.0 in 2019, then rose by 20.87% to $142061.0 in 2020, then surged by 41.95% to $201653.0 in 2021, then soared by 112.74% to $429000.0 in 2022.
  • Business Quant data shows Non-cash Items for KPRX at $429000.0 in Q3 2022, $473000.0 in Q2 2022, and $647000.0 in Q1 2022.